Advaxis, Inc. (NASDAQ:ADXS) Director Roni Appel bought 3,000 shares of the firm’s stock in a transaction on Wednesday, April 10th. The shares were bought at an average cost of $3.80 per share, with a total value of $11,400.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of ADXS traded down $0.13 during mid-day trading on Thursday, hitting $3.69. The company’s stock had a trading volume of 37,877 shares, compared to its average volume of 1,224,870. Advaxis, Inc. has a one year low of $2.70 and a one year high of $30.60. The stock has a market capitalization of $21.05 million, a price-to-earnings ratio of -0.19 and a beta of 3.95.

Advaxis (NASDAQ:ADXS) last posted its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported $0.18 earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.43. Advaxis had a negative return on equity of 101.51% and a negative net margin of 140.12%. The company had revenue of $19.69 million during the quarter. Equities research analysts anticipate that Advaxis, Inc. will post -2.4 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Virtu Financial LLC boosted its position in shares of Advaxis by 740.4% in the fourth quarter. Virtu Financial LLC now owns 176,213 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 155,246 shares during the period. Two Sigma Investments LP boosted its position in shares of Advaxis by 2,468.2% in the fourth quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 355,415 shares during the period. Deutsche Bank AG boosted its position in shares of Advaxis by 5,970.3% in the fourth quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock valued at $106,000 after acquiring an additional 553,031 shares during the period. BlackRock Inc. boosted its position in shares of Advaxis by 3.1% in the fourth quarter. BlackRock Inc. now owns 1,446,288 shares of the biotechnology company’s stock valued at $275,000 after acquiring an additional 43,368 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Advaxis by 173.0% in the third quarter. Renaissance Technologies LLC now owns 1,191,846 shares of the biotechnology company’s stock valued at $1,120,000 after acquiring an additional 755,352 shares during the period.

A number of brokerages have issued reports on ADXS. HC Wainwright set a $4.00 target price on Advaxis and gave the stock a “hold” rating in a research report on Friday, April 5th. ValuEngine cut Advaxis from a “buy” rating to a “hold” rating in a research report on Friday, January 25th. Finally, Zacks Investment Research raised Advaxis from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research report on Wednesday, February 20th.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.watchlistnews.com/insider-buying-advaxis-inc-adxs-director-buys-3000-shares-of-stock/2955512.html.

Advaxis Company Profile

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

Featured Story: Trading Strategy Methods and Types

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.